MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients - interview with Marco Valgimigli

Reported from the European Society of Cardiology ESC Congress 2021

ESC Congress 2021: Discover the interview given by Marco Valgimigli to Luis G. Ortega-Paz for PCRonline about the MASTER-DAPT trial to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events.

Why use precise-DAPT for patient selection? What do you recommend clinicians/interventionists to use in clinical practice?
Why did you select three co-primary endpoints? Why did you assess them in hierarchical order, and why do you choose that order?
MASTER-DAPT was performed with only one stent platform. Do you believe this affects the external validation of your results?
What should we do for the long-term treatment of high-bleeding risk (HBR) patients who completed the DAPT regimen? Restart life-long aspirin SAPT?
What are the future perspectives in the field of HBR and DAPT?
What further research will you be conducting in the field of HBR and DAPT?